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Background: Feline Panleukopenia (FPL) is a serious disease of cats that can be prevented by vaccination. Kittens
are routinely vaccinated repeatedly during their first months of life. By this time maternally derived antibodies
(MDA) can interfere with vaccination and inhibit the development of active immunity. The efficacy of primary
vaccination under field conditions was questioned by frequent reports to the Paul-Ehrlich-Institut on outbreaks of
FPL in vaccinated breeding catteries. We therefore initiated a field study to investigate the development of
immunity in kittens during primary vaccination against FPL.
64 kittens from 16 litters were vaccinated against FPL at the age of 8, 12 and 16 weeks using three commercial
polyvalent vaccines. Blood samples were taken before each vaccination and at the age of 20 weeks. Sera were
tested for antibodies against Feline Panleukopenia Virus (FPV) by hemagglutination inhibition test and serum
neutralisation assay in two independent diagnostic laboratories.
Results: There was a good correlation between the results obtained in different laboratories and with different
methods. Despite triple vaccination 36.7% of the kittens did not seroconvert. Even very low titres of MDA
apparently inhibited the development of active immunity. The majority of kittens displayed significant titres of MDA
at 8 and 12 weeks of age; in some animals MDA were still detected at 20 weeks of age. Interestingly, the vaccines
tested differed significantly in their ability to overcome low levels of maternal immunity.
Conclusions: In the given situation it is recommended to quantify antibodies against FPV in the serum of the
queen or kittens before primary vaccination of kittens. The beginning of primary vaccination should be delayed
until MDA titres have declined. Unprotected kittens that have been identified serologically should be revaccinated.Background
Feline Panleukopenia (FPL) is a contagious, serious dis-
ease of cats. The causative agent, Feline Panleukopenia
Virus (FPV), belongs to the genus Parvovirus of the virus
family Parvoviridae [1]. FPV is highly stable in the envir-
onment and endemic in many cat populations [2]. In a
retrospective study FPL was identified as cause of death in
25% of kittens sent in for pathological examination [3].
The virus predominantly replicates in rapidly dividing
cells. In newborn kittens, high mortality (>90%) with per-
acute deaths and neurological disorders like ataxia and
blindness are the main clinical signs. Older kittens develop
panleukopenia, neutropenia and diarrhoea due to* Correspondence: verena.jakel@pei.de
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reproduction in any medium, provided the orinfection of bone marrow, lymphatic tissue and intestinal
epithelial cells. Clinical disease is most often diagnosed in
kittens between 2 and 5 months of age while older cats
predominately undergo subclinical or mild forms of the
disease [2,4].
Vaccines against FPL are generally based on avirulent,
replication competent virus strains (modified live vaccines,
MLV). Successful vaccination induces virus-neutralising
antibodies that provide protection against clinical FPL [2,5-
7]. They can be used to monitor the immunological status
of an animal [8]. In kittens lacking maternal antibodies, vac-
cination with MLV leads to seroconversion with high and
long-lasting antibody titres [9,10]. Queens can transfer ma-
ternal antibodies mainly via colostrum conferring protec-
tion against disease during the first weeks of life [8,11]. The
individual status of maternal immunity has been reported
to differ considerably between kittens and is dependent ond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Test results of HI A negative sera (<1:10) by SNT B.
The inverse titre is shown. The vertical dotted line indicates the
arbitrary titre of 1:10 below which interference of MDA with
vaccination might not be expected.
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the quality of the colostrum and the time of nursing [12].
Maternally derived antibodies (MDA) interfere with the de-
velopment of active immunity after vaccination. Kittens
with MDA titres ≥1:10 measured by hemagglutination in-
hibition (HI) did not show seroconversion after vaccination
with a MLV [8]. Therefore, vaccination is not recom-
mended before the level of MDA has fallen below this
value. After the complete disappearance of MDA a single
vaccination with MLV may lead to seroconversion and high,
long-lasting titres [13].
While low titres of MDA do not generally provide pro-
tection against infection, they may still interfere with
vaccination [8]. The period between the disappearance
of protection by maternally derived passive immunity
and the ability to respond to vaccination with the devel-
opment of active immunity is referred to as “critical
phase” or “immunological gap”. During this period, a
high incidence of severe cases of FPL is observed [4].
Several attempts have been made to determine the opti-
mal vaccination age for kittens in order to shorten the
time at risk. Scott et al. suggested calculating the time
point, when MDA have fallen to a level allowing suc-
cessful vaccination, based on the antibody titre of the
queen [8]. Other authors suggested testing the offspring
prior to vaccination [14]. In the latter study performed
in dogs a significant correlation between the antibody
titres of littermates was observed.
Due to the lack of responsiveness in kittens with MDA
most manufacturers recommend double vaccination against
FPL at an interval of 3 to 4 weeks starting at the age of 6–
8 weeks for primary immunisation. In any case, the last
dose should be given beyond 12 weeks of age. Some manu-
facturers suggest postponing primary vaccination until
12 weeks of age if high MDA titres are expected. In this
case, application of the second dose is recommended at 16
to 20 weeks of age [15].
Current recommendations on vaccination against FPL
have been questioned by reports showing that protective
immunity is not achieved in a significant proportion of
cats. Dawson et al. observed a high number of kittens with-
out antibody response at the age of 15 weeks after two or
three vaccinations (25 and 39% respectively) [16]. Similar
results were obtained in other studies [17,18]. Reports of
severe disease in vaccinated animals indicate the clinical
significance of non-responding cats and dogs [4,19,20].
Since 2007 several outbreaks of FPL in vaccinated
breeding catteries of Norwegian Forest Cats (NFC) were
reported to the Paul-Ehrlich-Institut. The incidents were
treated as cases of suspected lack of expected efficacy
(SLEE). Subsequently we initiated a field study to investi-
gate the serological immune response of NFC after vac-
cination against FPL. Kittens were vaccinated three times
at four week intervals with commercially available FPLvaccines as recommended for primary vaccination by the
“German Standing Vaccination Committee Vet” [21]. The
development of antibody titres against FPV was moni-
tored in all animals until the age of 20 weeks.
The hemagglutination inhibition (HI) test is widely
used to determine the antibody titre against FPV [22-
24]. Since no international standard has been established
so far for any method the comparison of results from
different laboratories and test methods is difficult [25].
We therefore decided to combine the vaccination effi-
cacy study with a comparison of test methods and la-
boratory performance.
Results
Correlation of test results
All serum samples were tested in two diagnostic labora-
tories using two different methods, respectively. The
inter-laboratory variation and predictive values showed a
good correlation between methods (HI vs SNT: Lab A
0.983 Lab B 0.804) and laboratories (Lab A vs Lab B: HI
0.897 SNT 0.949). In general, low responding or high titre
sera were classified identical by both test methods and la-
boratories. Nevertheless, different cut-off values discrim-
inating negative from low titre sera had to be considered.
Laboratory A reported negative results for approxi-
mately half of the samples. In the majority of these sera,
low titres of neutralising antibodies were detected by SNT
B (Figure 1), indicating a higher sensitivity of this method.
For statistical analysis the results of 248 blood samples
from 62 kittens were available. Two kittens were excluded
from statistical analysis (Table 1): one kitten (NFC)
showed clinical signs of disease on the day of the first vac-
cination; for the other kitten (European House Cat - EHC)
no follow-up was possible.















I 3 14 2 10 24
II 3 15 2 6* 21
III 4 12* 2 7 19
Total 10 41 6 23 64
* Missing results led to the exclusion of one kitten in this group from the
statistical analyses. NFC =Norwegian Forest Cats, EHC = European House Cats.
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and EHC) were compared, no statistically significant dif-
ferences in the humoral immune response were observed
(p >0.05). As a consequence the differentiation between
breeds was dismissed for the remaining analyses.
Maternal antibodies can persist for extended periods of
time
All queens tested (12/15) had high antibody titres (SNT
B; range from 1:46.8 to 1:34092) before birth or on the
day of the first or second vaccination of the kittens.Figure 2 Development of antibody titres against FPV in kittens durin
shown. The vertical dotted line indicates the arbitrary titre of 1:10 below w
kittens were vaccinated three times with 8, 12 and 16 weeks of age. Alloca
antibodies) was based on the antibody course in the individual animal as e
and passive immunity at 8 weeks was unclear and the antibodies titled asWhen the kittens were tested prior to the first vaccin-
ation at 8 weeks of age 92% of them had antibodies against
FPV (Figure 2 and Figure 3). Detected antibody titres can
either represent MDA or be the result of an early infection
with FPV. For differentiation the course of antibody titres
during the study was evaluated in each individual animal.
Six kittens showed a significant increase in antibody
titres after the first vaccination. The remaining kittens
showed decreasing antibody titres after first vaccination
indicating maternal antibodies. In a high number of ani-
mals, antibody titres further decreased after the second
and even after the third vaccination indicating MDA as
well. Overall, MDA were observed in many kittens at 8
and 12 weeks of age (Figure 2) and in 4 kittens at 20 weeks
of age. The calculated half-life of MDA was 8.8 days on
average (litter range 6–11 d).
Two littermates had high antibody titres >1:1000 (SNT
B) already before the first vaccination remaining at this
level during the time of the study (Figure 2 and Figure 3).
Apparently, these kittens had been exposed to natural
infection.
In two littermates from a litter of three kittens, no
antibodies were detected during the entire study.g primary vaccination measured by SNT B. The inverse titre is
hich interference of MDA with vaccination might not be expected. All
tion to the respective group (maternal, infection, vaccination
xplained in the text. In some kittens differentiation between active
“undefined”.
Figure 4 Relationship between the antibody titres of the queen
and their kittens measured by SNT B 8 weeks after birth. The
horizontal dotted line indicates the arbitrary titre of 1:10 below
which interference of MDA with vaccination might not be expected.
Table 2 Effect of the queens’ antibody titre on
vaccination results of the kittens
antibody titre of the queen <1000 1000–<10000 >10000
seroconversion of kittens: N % N % N %
after first vaccination 4 25 0 0 2* 9
after second vaccination 9 56 5 36 0 0
after third vaccination 1 6 6 43 4 17
no seroconversion 2 13 3 21 17 74
Total 16 14 23
*In this litter the third littermate died from FPL by the time of first vaccination.
Figure 3 FPV antibody titres and the time point of
seroconversion in kittens measured by SNT B. The mean titre
and the SEM are shown. The horizontal dotted line indicates the
arbitrary titre of 1:10 below which interference of MDA with
vaccination might not be expected.
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Reaction patterns between littermates were generally simi-
lar. In 10 of the 16 litters all kittens seroconverted following
the same vaccination and in 5 litters the kittens reacted to
consecutive vaccinations (data not shown). When titres
were compared at 8 weeks of age there was low variability
between littermates with differences of up to 1:2 in 11 litters
(72%), 1:4 in three and 1:16 in one litter (HI A).
Absence of seroconversion in a high number of kittens
despite repeated vaccinations
In our study seroconversion did not occur in 36.7% of the
kittens despite triple vaccination (Figure 2). There was a
relationship between the presence of MDA and the prob-
ability of seroconversion. After seroconversion antibody
titres remained relatively constant at high levels in all
kittens.
Despite the absence of detectable HI antibodies (HI
A; <1:10), no seroconversion was found in 70% of the
samples (data not shown); 37% of the kittens had
titres <1:10 twice and 33% three or four times in a
row. When the results of SNT B were analysed, the
number of animals that did not seroconvert despite
the absence of detectable antibodies (1:1.7) dropped
to 49% with 25% of the kittens consecutively reacting
negative twice. This indicates that even minimal anti-
body titres beyond the detection level of the assays
are capable to inhibit seroconversion.
Correlation between the antibody titre of the queen and
seroconversion rate of kittens
The antibody levels of the queens correlated with the MDA
titre of the respective kittens (Figure 4) as well as with the
vaccination performance. Queens with low antibody titres
had a higher percentage of successfully immunised kittensshowing seroconversion at earlier time points (Table 2). 14
out of 16 kittens from queens with antibody titres <1:1000
(SNT B) seroconverted during the study: 25% after the first
vaccination and 56% after the second vaccination. In con-
trast no seroconversion was observed in the majority of kit-
tens (17/23) from queens with antibody titres >1:10000.
Two kittens from a queen with a high antibody titre
(1:3788) showed rising antibody titres after the first vaccin-
ation. The reaction of these animals may have been the re-
sult of natural infection seen in this litter (Table 2).
Calculation of starting points avoids unnecessary
vaccinations
The apparent correlation between antibody titres of queens
and the response of their kittens to vaccination allows im-
provement of the vaccination schedule. Along this line we
calculated the starting point for primary vaccination based
on antibody titres of the queen determined by SNT B. The
starting point was defined as the calculated age when MDA
will reach the titre value of 1:10.
68% of the kittens that seroconverted during the study
showed a serological response after vaccination at the cal-
culated starting point or later (data not shown). The re-
sponse rate using a modified vaccination scheme including
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lowed by revaccination 4 weeks later was comparable to the
triple vaccination scheme.
Similar results were obtained when the calculation of
the starting point was based on individual antibody titres
of kittens. 50% of kittens that seroconverted responded
to a vaccination given when the calculated titre of MDA
was ≤1:10. Based on our data we set up the respective
equation for calculation as follows:
a ¼ age þ 8:8 ln titre
ð Þ  ln bð Þ
ln 2ð Þ
*in days of blood sampling
**on day of blood sampling
a = age of the kitten when its MDA titre will reach the
specified titre “b”
In order to determine the success of vaccination discrim-
ination between actively induced antibodies and MDA is es-
sential. In animals older than 12 weeks, high titres
(>1:1000) measured by both test systems could be assigned
to active immunity after seroconversion in nearly all cases
(Figure 2). With antibody titres below 1:1000 differentiation
between MDA and active immunity was not feasible, even
beyond 12 weeks of age.
Significant influence of vaccines
In our study we used three different commercially avail-
able vaccines based on replication competent FPV. The
statistical analysis of SNT results demonstrated significant
differences between vaccines of different manufacturers
(Lab A: p=0.0388; Lab B: p=0.0066). Virtually all animals
with repeated minimum titre results after vaccination
belonged to group I. In this group, a negative serum titre
(1:1.7, SNT B) was predictive for seroconversion after a
following vaccination only in one third of the cases. In
contrast a negative result was followed by seroconversion
in virtually all cases in groups II and III.
In some animals seroconversion occurred despite
titres >1:10. All respective animals belonged to vaccination
group II.
Discussion
The aim of the current study was to evaluate the efficacy
of vaccines against Feline Panleukopenia (FPL) under field
conditions. The indicator chosen was the development of
antibody titres after vaccination, which is a commonly
used indirect method. FPL is a serious health risk espe-
cially to young cats. Neutralising antibodies, passively
acquired or due to active immunity, are known to confer
protection against the disease [2,5-8]. Maternally derived
antibodies (MDA) interfere with the development of ac-
tive immunity after vaccination [8,11,25,26]. In a study
based on one vaccine Scott came to the conclusion thatby 12 weeks of age MDA titres have declined to levels that
are overcome by MLV [27]. Our data demonstrate that
this assumption should not be generalized. We found anti-
body titres likely to represent MDA in most kittens until
12 weeks of age and beyond. As a consequence, only 45%
of the kittens were successfully immunised by a twofold
vaccination at 8 and at 12 weeks, representing the immun-
isation scheme recommended for primary vaccination by
most manufacturers. Even application of a third vaccine
dose at 16 weeks of age left one out of three kittens un-
protected. Our findings are in line with results from previ-
ous field studies. Dawson et al. showed that only 75% of
kittens seroconverted after multiple vaccinations until
12 weeks of age [16]. Similar results were reported in re-
cent studies [17, 18]. The lack of successful immunisation
following the recommended vaccination scheme explains
the occurrence of clinical disease in the post-weaning
period both in vaccinated as well as non-vaccinated ani-
mals [4]. The inability to induce a significant serological
response (i.e. seroconversion) implicates complete neutral-
isation of the vaccine virus. Consequently priming effects
leading to an enhanced serological response after revac-
cination as postulated by Poulet as well as the induction
of cell mediated immunity cannot be expected [17]. This
was demonstrated by the high percentage of kittens re-
quiring three vaccinations until seroconversion and the
large proportion that failed to seroconvert despite triple
vaccination. Furthermore it has been shown that kittens
and puppies are susceptible to parvovirus infection after
disappearance of passive immunity in spite of previous
infections with virulent FPV or CPV during the phase of
protection by MDA [8,28]. Along this line vaccinations
with MLV that do not induce seroconversion must be
regarded as needless. It must be assumed that the animals
remain susceptible to FPV infection despite vaccination.
We found that in some animals even without detectable
levels of antibodies vaccination was unsuccessful. Similar
observations have been reported from studies in puppies
[28]. The reason for the vaccination failure observed in
the latter animals is not clear. Levels of interfering anti-
bodies below the detection limit of the test systems may
be responsible. Interestingly we observed significant differ-
ences between individual vaccines in their performance in
MDA-positive kittens (p <0.05). Seroconversion in the
presence of MDA titres >1:10 was only observed in ani-
mals from vaccination group II.
Our study was designed to evaluate the immune
response in different cat breeds and between littermates.
The number of litters in each group was therefore
limited. Since the statistical model considered the litter
size, results with regard to effects of different vaccines
are reliable. Further field studies should address the
efficacy of different vaccines during primary vaccination
of young kittens.
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antibody titres and their ability to respond to immunisation
our results partly support previous studies. Friedrich found
a high correlation between the HI- antibody titres of litter-
mates in a study in dogs including 58 litters [14]. 97% of
the puppies had HI-antibody titres that differed from the
titres of their littermates not more than a single titre step
(dilution 1:2). The variability of antibody titres in kittens of
the same litter observed in our study was slightly higher.
Nevertheless, the reaction pattern within a litter was simi-
lar: in 2/3 of the litters seroconversion was induced in all
kittens following the same vaccination. Apparently litter-
mates are susceptible to vaccination at similar time points
allowing generalisation of test results of individual animals
within a litter.
In addition we found a close relationship between antibody
titres of the queens and the kinetics of MDA titres in the
respective kittens which is in line with previous reports [8].
Our results demonstrate that the current recommen-
dations on primary vaccination of kittens should be
revised. Titres of MDA in kittens mainly depend on the
immunological status of their queen. In homogenous
litters with good colostrum supply similar maternally
derived immunity can be expected. The majority of
kittens in our study were from middle-aged vaccinated
breeding cats and displayed relatively high MDA titres.
In contrast, Dawson et al. found a high percentage of
kittens from rescue shelters serologically negative at the
age of 6 weeks [16]. For optimal vaccination results the
primary vaccination scheme should be adapted to the
situation of the individual kitten or litter. We propose to
start vaccination at the age when kittens show low MDA
titres corresponding to the ability to raise an active im-
mune response. In previous publications the critical
MDA titre was determined as ≤1:10 [8]. The results of
our study generally confirm this assumption showing
that about two-thirds of kittens will develop an active
immunity after single vaccination at this starting point
or thereafter. Therefore, we recommend measuring the
antibody titre either of the queen or of kittens to calcu-
late the starting point for vaccination. Identification and
revaccination of unprotected animals by individual post-
vaccination efficiency control is another key factor to
increase the success rate of vaccination against FPL. It
should be noted however that titre values refer to spe-
cific test systems and standardisation between methods
is generally missing.
There were some immanent limitations of our study.
Monitoring of infection status was not performed. This
might have led to overestimation of vaccination efficacy if
seroconversion was induced by natural infection instead
of vaccination. Challenge infections to test immunity were
not performed. Therefore only indirect conclusions on
vaccination efficacy based on the development of theantibody titres can be drawn. Despite these limitations we
would like to stress that the current study is the first con-
taining independently collected data to assess the vaccin-
ation efficacy of FPL vaccines in the field.
Conclusions
Our study revealed serious problems associated with pri-
mary vaccination against FPL. A significant proportion
of kittens failed to develop active immunity following
the recommended vaccination scheme.
The results help to explain the high incidence of
clinical disease despite good vaccination coverage.
Additional studies on the performance of different
vaccines in the presence of MDA in combination with
epidemiologic data on disease incidence and vaccine
breakdowns are necessary for final adaptation of the
vaccination recommendations. The epidemiologic situation
may be improved by the development of new generation
vaccines that overcome passive immunity more easily.
Meanwhile, adjustment of the starting point for primary
vaccination to the individual situation of each kitten





If possible, a serum sample from the queen was obtained
approximately 1 week before giving birth and on the day
of the first vaccination of the kittens (8 weeks after
birth). Samples from 12 queens were available for ana-
lysis. In one queen the sample was taken on the day of
the second vaccination of the kittens (12 weeks after
birth).
Kittens
Breeders and owners of NFC and European house cats
(EHC) were recruited. In two litters of EHC the breeding
history was unknown and the queen was not available.
Complete litters of each breed were assigned to one of
three vaccination groups (I, II and III). The numbers of
litters and animals per group are indicated in Table 1.
Vaccinations
Kittens were vaccinated at 8, 12 and 16 weeks of age
using three commercially available polyvalent life vac-
cines against FPL and cat flu (RC - rhinotracheitis,
calicivirus infection). Upon request of the owners,
vaccines against chlamydiosis, feline leukaemia and
rabies were also given. Vaccinations were performed
following the product information supplied by the
manufacturers. The vaccine ranges used were Nobivac
from Intervet, Purevax from Merial and Virbagen felis
from Virbac (in alphabetical order).
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A blood sample was taken from each kitten immediately
prior to vaccinations at 8 (pre-vaccination control), 12 and
16 weeks of age. A final blood sample was obtained at
20 weeks of age. The sera were prepared by centrifugation,
labelled individually with a serial number and stored
at −20°C until testing. The sera of the queens were treated
accordingly. After receipt of the last sample, the sera were
thawed and aliquoted. The sample numbers were rando-
mized and blinded. One aliquot of each serum was sent to
two independent diagnostic laboratories (Laboratory A
and Laboratory B).
Hemagglutination inhibition (HI) tests
The HI test was performed in both laboratories according
to the same protocol. The sera were diluted in PBS and
pretreated by heat inactivation (30 min, 56°C) followed by
incubation with 12.5% (w/v) kaolin suspension for 20 min
at room temperature. After removal of kaolin by centrifu-
gation the supernatant was pre-adsorbed to swine erythro-
cytes for 1 h at 37°C and subsequently diluted in borate
buffer (BBS pH 9.0) over twelve steps in a geometrical 1:2
series starting at 1:10 in 96-well round bottom plates
(Greiner, Frickenhausen) [29]. To each well 4–8 hemag-
glutinating units of feline parvovirus (strain 292, provided
by U.Truyen Leipzig) in BBS were added and incubated
for 1 h at 18–25°C. After cooling of the plates to 4°C a 1%
suspension of pig erythrocytes in phosphate buffer
(0.15 M NaCl 0.3 M NaH2PO4, pH 4.5) was added. Fol-
lowing an incubation period of 90–120 min at 4°C the
plates were read macroscopically. The HI titer was given
as the highest dilution of serum showing complete inhib-
ition of hemagglutination. Control reactions without virus
antigen were used to exclude nonspecific effects.
Serumneutralisation tests (SNT)
Laboratory A
For the titration of neutralising antibodies heat inacti-
vated sera were prediluted 1:10 followed by duplicate
geometrical 1:2 dilution series prepared directly in 96-
well plates. To each well 100 TCID50 of FPV (strain 292)
were added and incubated for 1 h at 37°C. After addition
of indicator cells (CRFK, ATCC CCL-94) the plates were
incubated for 5 days at 37°C in a humified cell culture
incubator. Reading of the test results was done by indir-
ect immune fluorescence using monoclonal antibodies
followed by goat anti-mouse FITC-conjugated IgG (Dia-
nova, Hamburg) [30]. The titre was given as the last di-
lution step with complete neutralisation.
Laboratory B
The test was essentially performed as in Laboratory A
with minor changes: (i) sera were diluted in a geometrical
1:3 series and (ii) antibodies used for immune fluorescencestaining were CPV1-2A1 (Acris, Herford) as first antibody
followed by goat anti-mouse H+L conjugated to Cy3
(Dianova, Hamburg). Titres were calculated according to
the method of Spearman and Kärber.Interpretation of test results
Interpretation of test results was performed in accordance
with the guidelines supplied by the test laboratories. For
the HI test antibody titres ≥1:10 were regarded as positive
by both test laboratories. Different cut off values were
used for the two SN assays: Laboratory A ≥1:10 and La-
boratory B >1:1.7. A difference of antibody titres in con-
secutive sera of the same animal by a factor of at least 4
(HI and SNT A) or 5.2 (SNT B) was regarded as signifi-
cant, i.e. demonstrating seroconversion.Statistical analysis
The statistical analysis was performed separately for
each laboratory (A, B) and the two methods (HI, SNT)
for the logarithmic titres in a mixed-linear model for
repeated measurements. The fixed factors were time
(week of blood sampling after birth), breed (NFC, EHC),
vaccine (I, II or III) and interaction between breed and
vaccine. As random factors litter and animal (repeated
measures) were included in the calculation. P-values
and confidence intervals were calculated and α-adjusted
by the method of Bonferroni. Values of p <0.05 were
considered significant.
The half-life of maternal antibodies was calculated as
described by Scott et al. [8]. For calculation of the earli-
est time point for successful vaccination based on the
antibody titre of the queen, the equation set up by Scott
et al. was used: “x = 4.5*(q-y), where x is the age of the
kitten at which the maternally derived titre of this kitten
will reach the specified -log value y and q is the -log titre
of the queen” [8].
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